Synovate Launches Hepatitis C Monitor

Synovate Healthcare has extended its US portfolio of anti-viral research with the launch of a Hepatitis C Monitor. The company already runs two services for the anti-viral market, Global HIV and Hepatitis B monitors.

The new Monitor is based on regular reports from a representative panel of physicians treating HCV patients in the US. In addition to patient record information, it also collects physician perceptions of the market and the disease for comparative purposes. A European launch is planned for 2006.

The Monitor has been launched in anticipation of rapid changes in the hepatitis C treatment market: the severity of the disease and the limited treatment options currently available make it a key area of interest for the pharmaceutical industry. There are over 20 products in the pipeline, many of which are still in early stage development. The Monitor will help clients develop viable doctor and patient segmentation models and track how the disease is perceived, managed and treated over time.

According to Clarissa Del Pup, Manager of the Hepatitis Monitors, 'We are extremely excited about this launch - we can offer clients an extensive portfolio of products within the anti-viral market; analysing the dynamics of this Hepatitis C market whilst gaining a helicopter view of overall brand performance and co-infection'.

Synovate Healthcare's home page is at www.synovate.com/healthcare

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.

• Synovate USA
• All news
• MrWeb info